Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pluristem Therapeutics (PSTI) Gains Following Positive PLX-PAD Cells Preclinical Data in DMD
- Ford's Indonesian dealers demand compensation after abrupt withdrawal
- Needham & Company Weighs in on Brexit Biotech Impact (ACAD) (GILD0 (ICPT) (SGEN)
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!